L
Lynn D. Cornell
Researcher at Mayo Clinic
Publications - 161
Citations - 14960
Lynn D. Cornell is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Kidney disease & Kidney. The author has an hindex of 52, co-authored 150 publications receiving 12291 citations. Previous affiliations of Lynn D. Cornell include University of Alberta & Harvard University.
Papers
More filters
Journal ArticleDOI
Consensus statement on the pathology of IgG4-related disease
Vikram Deshpande,Yoh Zen,John Kc Chan,Eunhee E Yi,Yasuharu Sato,Tadashi Yoshino,Günter Klöppel,J. Godfrey Heathcote,Arezou Khosroshahi,Judith A. Ferry,Rob C. Aalberse,Daniel Bloch,William R. Brugge,Adrian C Bateman,Mollie N. Carruthers,Suresh T. Chari,Wah Cheuk,Lynn D. Cornell,Carlos Fernandez-del Castillo,David G. Forcione,Daniel L. Hamilos,Terumi Kamisawa,Satomi Kasashima,Shigeyuki Kawa,Mitsuhiro Kawano,Gregory Y. Lauwers,Yasufumi Masaki,Yasuni Nakanuma,Kenji Notohara,Kazuichi Okazaki,Ji Kon Ryu,Takako Saeki,Dushyant V. Sahani,Thomas C. Smyrk,James Robert Stone,Masayuki Takahira,George Webster,Motohisa Yamamoto,Giuseppe Zamboni,Hisanori Umehara,John H. Stone +40 more
TL;DR: This statement proposes a terminology scheme for the diagnosis of IgG4-related disease that is based primarily on the morphological appearance on biopsy, and advocates the use of strict criteria for accepting newly proposed entities or sites as components of the IgG 4- related disease spectrum.
Journal ArticleDOI
Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions
Mark Haas,Banu Sis,Lorraine C. Racusen,Kim Solez,Denis Glotz,Robert B. Colvin,Maria Castro,D. S. R. David,Elias David-Neto,Serena M. Bagnasco,Linda C. Cendales,Lynn D. Cornell,Anthony J. Demetris,Cinthia B. Drachenberg,Carol Farver,Alton B. Farris,Ian W. Gibson,Edward S. Kraus,Helen Liapis,Alexandre Loupy,Volker Nickeleit,Parmjeet Randhawa,E. R. Rodriguez,David N. Rush,Rex Neal Smith,Carmela D. Tan,William D. Wallace,Michael Mengel +27 more
TL;DR: The 12th Banff Conference on Allograft Pathology was held in Comandatuba, Brazil, from August 19-23, 2013, and was preceded by a 2-day Latin American Symposium on Transplant Immunobiology and Immunopathology.
Journal ArticleDOI
The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials
Mark Haas,Alexandre Loupy,Carmen Lefaucheur,Candice Roufosse,Denis Glotz,Daniel Serón,Brian J. Nankivell,Philip F. Halloran,Robert B. Colvin,Enver Akalin,Nada Alachkar,Serena M. Bagnasco,Yassine Bouatou,Yassine Bouatou,Jan U. Becker,Lynn D. Cornell,J.-P. Duong Van Huyen,Ian W. Gibson,Edward S. Kraus,Roslyn B. Mannon,Maarten Naesens,Volker Nickeleit,Peter Nickerson,Dorry L. Segev,Harsharan K. Singh,Mark D. Stegall,P. Randhawa,Lorraine C. Racusen,Kim Solez,Michael Mengel +29 more
TL;DR: The Banff ABMR criteria are updated and paves the way for the Banff scheme to be part of an integrative approach for defining surrogate endpoints in next‐generation clinical trials.
Journal ArticleDOI
Recommendations for the nomenclature of IgG4-related disease and its individual organ system manifestations
John H. Stone,Arezou Khosroshahi,Vikram Deshpande,John K.C. Chan,J. Godfrey Heathcote,Rob C. Aalberse,Atsushi Azumi,Daniel Bloch,William R. Brugge,Mollie N. Carruthers,Wah Cheuk,Lynn D. Cornell,Carlos Fernandez-del Castillo,Judith A. Ferry,David G. Forcione,Günter Klöppel,Daniel L. Hamilos,Terumi Kamisawa,Satomi Kasashima,Shigeyuki Kawa,Mitsuhiro Kawano,Yasufumi Masaki,Kenji Notohara,Kazuichi Okazaki,Ji Kon Ryu,Takako Saeki,Dushyant V. Sahani,Yasuharu Sato,Thomas C. Smyrk,James R. Stone,Masayuki Takahira,Hisanori Umehara,George Webster,Motohisa Yamamoto,Eunhee S. Yi,Tadashi Yoshino,Giuseppe Zamboni,Yoh Zen,Suresh T. Chari +38 more
TL;DR: John H. Stone, Arezou Khosroshahi, Vikram Deshpande, John K.Stone, Masayuki Takahira, Hisanori Umehara, George Webster, Motohisa Yamamoto, Eunhee Yi, Tadashi Yoshino, Giuseppe Zamboni, Yoh Zen, and Suresh Chari.
Journal ArticleDOI
Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients.
Mark D. Stegall,Tayyab S. Diwan,Suresh Raghavaiah,Lynn D. Cornell,Justin M. Burns,Justin M. Burns,Patrick G. Dean,Fernando G. Cosio,Manish J. Gandhi,Walter K. Kremers,James M. Gloor +10 more
TL;DR: Inhibition of terminal complement activation with eculizumab decreases the incidence of early AMR in sensitized renal transplant recipients (ClincalTrials.gov number NCT006707).